NCT06513286View on ClinicalTrials.gov

TherVacB - A Heterologous Protein Prime/MVA Boost Therapeutic Hepatitis B Vaccine Candidate

PHASE1/PHASE2Enrolling by invitationINTERVENTIONAL
Enrollment

81

Participants

Timeline

Start Date

June 12, 2025

Primary Completion Date

December 31, 2026

Study Completion Date

December 31, 2026

Conditions
Chronic Hepatitis B
Interventions
BIOLOGICAL

TherVacB (HEPLISAV B +/- HBcoreAg + MVA-HBVac)

Administration of the described combinations via the intramuscular route

BIOLOGICAL

TherVacB (2xHEPLISAV B + HBcoreAg + MVA-HBVac)

Administration of the described combinations via the intramuscular route

Trial Locations (6)

20246

Investigational Site UKE, Hamburg

30625

Investigational Site MHH, Hanover

60590

Investigational Site GUF, Frankfurt

81337

Investigational Site LMU, Munich

81675

Investigational Site TUM, Munich

04103

Investigational Site Uni Leipzig, Leipzig

All Listed Sponsors
collaborator

Institute of Virology Helmholtz Zentrum München Trogerstraße 30 81675 Munich, Germany

UNKNOWN

lead

Michael Hoelscher

OTHER